Akums Drugs and Pharmaceuticals

Listing Details
BSE : 544222 | NSE : AKUMS
Industry : Pharma Formulations | ISIN : INE09XN01023 | FreeFloat : 10.00% | FnO : No | LotSize : N/A
Indices containing this Stock
BSE 250 Microcap | Nifty Smallcap 250
Valuation (Rs. Cr)
Intellectual Capital (IC)869.33
Net Worth (NW)3,128.30
Intrinsic Worth (IW)3,997.63
Market Cap (MC)9,213.84
Economic Value Added-112.56
Assumptions
%
%
IC Ratios
Knowledge Basis (IC/IW)21.75%
IC Gross Margin (EBITDA/IC)59.86%
IC Net Margin (NPT/IC)39.37%
Knowledge Turnover (Sales/IC)4.73
Market to Intrinsic Value (MC/IW)2.30
Stock Price
As OfIntrinsic ValueMarket Price
30 Jun 2025Rs. 253.99Rs. 585.40
4 Nov 2025 ---- Rs. 471.10
3.45     0.73%
Stock Sentimeter
Fundamental - QualityTechnical - Daily Price actionNear-term Outlook
EVA > 0 : NoBearish10 DMA : Rs. 465.04BullishWeak Bearish
KB > 50% : No50 DMA : Rs. 462.48
0 < M2IV < 1 : NoVol-Price trend : Rising
Disclaimer: Sentimeter is based on market data calculations and is NOT an investment advice
Question 3 - Is this stock undervalued?
Intrinsic Value v/s Book Value v/s Market Price over Time
Question 2 - Does this business have significant knowledge assets?
Knowledge Basis over Time
Question 1 - Is this business generating enough profits to cover its cost of capital?
EVA® over Time
* EVA is a registered trademark of Stern Stewart and Co.
Quarterly Results (Rs. Cr)
Quarter
Type*
Sales
Income
EBITDA
EBIT
PBT
PAT
NPT
Jun-23
C
969.89
977.98
-117.18
-146.89
-159.04
-187.43
-187.75
Sep-23
C
1181.25
1188.03
158.61
128.19
114.53
32.69
32.61
Dec-23
C
1082.77
1091.75
102.35
70.80
58.36
195.00
191.35
Mar-24
C
944.21
954.45
13.23
-20.72
-33.10
-39.47
-39.09
Jun-24
C
1019.11
1025.66
134.56
100.50
87.48
61.21
61.84
Sep-24
C
1033.09
1046.56
134.66
99.79
87.89
66.65
65.77
Dec-24
C
1010.41
1024.97
135.93
91.41
86.27
66.31
66.31
Mar-25
C
1055.55
1073.09
111.46
71.46
66.92
149.61
149.61
Jun-25
C
1024.03
1050.76
155.70
118.78
95.65
64.69
64.69
* C - Consolidated, S - Standalone

Standard Disclaimer

  1. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
  2. Past performance, by way of backtesting or by way of actuals, is no guarantee of future returms.
  3. Data mentioned on this page is for educational purpose only and does not constitute investment advice.
Standard Warning - Investment in securities markets are subject to market risk. Read all the related documents carefully before investing.